'
Zydus
Lifesciences hosted a conference call on Nov 6, 2025. In the conference call,
the company was represented by, Dr. Sharvil Patel, Managing Director.
Key takeaways of the call
In
Q2 FY26, the India business contributed 37% to the total revenue, with
Formulations accounting for 26% and Consumer Wellness for 11%. US Formulations
contributed 45%, International Formulations 13%, APIs 2%, and Medtech and
others 3%.
In
Q2 FY25, the India Formulations business grew 8.4% YoY, Consumer Wellness was
up 30.7% YoY, US Formulations rose 13.5% YoY, and International Formulations
increased 39.4% YoY. Revenue from the API segment increased 23.3% YoY, and the
Alliances & Others segment was down 85.1% YoY.
In
H1 FY26, the India business contributed 37% to the total revenue, with
Formulations accounting for 25% and Consumer Wellness for 12%. US Formulations
contributed 47%, Internation...
Pleaselogin & subscribe to view the full report.
More Reports
-
(26-Feb-2026)
Foseco India
Net down 35% on higher EO Exp
-
(26-Feb-2026)
KSB
Net up 11%, sales up 8%
-
(26-Feb-2026)
Sanofi India
OP down 23.67%
-
(25-Feb-2026)
Schaeffler India
Revenue jumps 28% and profit spurts 36% in Q4CY25
|
|